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A b s t r a c t
Background: Transcatheter aortic valve implantation (TAVI) is an established treatment method in selected high-risk patients 
with severe aortic stenosis. However, data on which patients gain most benefit from this procedure is still limited. According 
to the European consensus document, TAVI is recommended for high-risk patients with logistic EuroSCORE (log ES) ≥ 20%. 
To date, little is known about TAVI outcomes in patients with log ES < 20%.
Aim: To evaluate outcomes of TAVI in high-risk patients with log ES ≥ 20% in comparison with high-risk patients with log ES < 20%.
Methods and results: Of 93 patients who underwent TAVI at our institution between January 2009 and December 2011, we 
identified 59 (63.4%) patients with log ES ≥ 20% (Group 1) and 34 (36.6%) patients with log ES < 20% (Group 2). The mean 
log ES was 30.9 ± 9.7% in Group 1 and 12.7 ± 4.9% in Group 2 (p < 0.01). Significant differences were found between 
the two groups in regard to age (82.9 ± 5.9 vs. 78.7 ± 7.8 years, p = 0.001), left ventricular ejection fraction (51.5 ± 14% 
vs. 60.4 ± 9.6%, p = 0.002), pulmonary artery systolic pressure (56 ± 11 vs. 49 ± 10.6 mm Hg, p = 0.02), and glomerular 
filtration rate (51.3 ± 18.4 vs. 60.6 ± 16.6 mL/min/m2, p = 0.02). Survival rates at 1 and 2 years were 76.6% and 69.0% in 
Group 1 and 89.0% and 83.6% in Group 2 (p = NS). However, cardiovascular mortality at 1 and 2 years was higher in Group 
1 compared to Group 2 (21.4% and 28.6% vs. 8.1% and 10.8% in Groups 1 and 2, respectively). 
Conclusions: The results of this study demonstrate that at 2 years of follow-up, TAVI in high-risk patients with log ES ≥ 20% 
was associated with a higher cardiovascular mortality compared to high-risk patients with log ES < 20%. 
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INTRODUCTION
Transcatheter aortic valve implantation (TAVI), performed 
for the first time in 2002, is widely used in the treatment of 
selected patients with severe degenerative aortic stenosis (AS). 
In patients with haemodynamically significant AS, TAVI was 
shown to significantly improve exercise capacity and increase 
survival compared to medical treatment [1–5].
Determination of the operative risk is of major importance 
when selecting patients with significant AS for surgical aortic 
valve replacement (AVR) or TAVI. Risk scores most commonly 
used for this purpose include the Society of Thoracic Surgeons 
(STS) Risk Score and the logistic EuroSCORE (log ES), replaced 
by the EuroSCORE II in 2012 [6, 7]. While these risk scores 
were designed for the evaluation of surgical risk, no risk scores 
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have been specifically developed for the evaluation of TAVI 
procedural risk. In routine clinical practice, patients with 
low to moderate surgical risk are referred for surgical AVR, 
and high risk patients are referred for TAVI. According to the 
2008 joint position statement of the European Association 
for Cardio-Thoracic Surgery (EACTS), the European Society of 
Cardiology (ESC), and the European Association of Percutane-
ous Cardiovascular Interventions (EAPCI), TAVI is indicated 
in patients with log ES ≥ 20% or STS > 10%, while lower risk 
patients should be referred for surgical valve replacement [8]. 
According to the 2012 ESC guidelines on the management of 
valvular heart disease, the decision regarding the treatment ap-
proach in patients with AS should be made by the Heart Team 
[9]. The superior role of the Heart Team has been highlighted 
due to the fact that available risk scores do not include many 
clinical and anatomical factors associated with a significant 
increase in the operative risk. For this reason, the Heart Team 
often selects TAVI also in patients with log ES < 20% in whom 
concomitant conditions make the actual operative risk higher 
that estimated using the cardiac surgical risk scores.
In previously published studies, TAVI outcomes were 
mostly compared between patients deemed not to be can-
didates for surgery due to log ES ≥ 20% or STS ≥ 10% and 
moderate risk patients (log ES < 20% or STS < 10%) [10–13]. 
In these reports, it has not been stated whether the patients 
with log ES < 20% were deemed not to be candidates for sur-
gical treatment. Thus, it is unclear what is the effect of log ES 
on TAVI outcomes in high-risk or inoperable patients. The 
aim of the present study was to compare TAVI outcomes in 
patients with log ES ≥ 20% or < 20% who were selected for 
TAVI by the Heart Team due to concomitant conditions that 
were not included in the log ES algorithm but were associated 
with a significant increase in the operative risk.
METHODS
Transcatheter aortic valve implantation procedures have 
been performed at the National Institute of Cardiology in 
Warsaw-Anin since January 2009. Patients with severe symp-
tomatic AS with valve area < 1.0 cm2 and mean transvalvular 
pressure gradient > 40 mm Hg are selected for the procedure. 
All candidates for TAVI underwent routine laboratory testing, 
invasive or multidetector computed tomography (CT) coronary 
angiography, transthoracic echocardiocardiography (TTE), 
transoesophageal echocardiocardiography (TEE), CT of the 
lower limbs, aorta and the aortic valve, spirometry, gastros-
copy, carotid Doppler ultrasound, and neurology evaluation. 
Aortic valve anatomy and diameter were evaluated by TTE, 
TEE, and CT. The importance of specific diagnostic modali-
ties when selecting patients for TAVI, contraindications to this 
procedure, the criteria of prosthetic valve selection, and selec-
tion of the access route have been described previously [14].
All patients selected for TAVI were not considered suit-
able candidates for surgical valve replacement by the Heart 
Team. The reason for inoperability was high operative risk, i.e. 
log ES ≥ 20%, or in patients with log ES < 20%, the presence 
of concomitant conditions that significantly increased the risk 
of surgical valve replacement. The patients were divided into 
two groups: Group 1 with log ES ≥ 20%, and Group 2 with 
log ES < 20%. Reasons for selecting TAVI in the latter group 
were detailed in ‘Results’.
The patients were implanted with a balloon-mounted 
Edwards Sapien valve (Edwards Lifesciences, Irvine, CA, USA), 
currently available in a modified from as Sapien XT valve, or 
a CoreValve device (Medtronic CoreValve, Irvine, CA, USA). 
Details of the TAVI procedure were reported previously [14]. 
Following TAVI, all patients underwent outpatient follow-up 
at the National Institute of Cardiology in Warsaw. Follow-up 
visits were scheduled at 1 and 6 months after the procedure, 
followed by every 12 months. Follow-up was censored in case 
of the patient’s death.
Statistical analysis
Continuous variables were shown as mean values ± stand-
ard deviation, and categorical variables as percentage fre-
quencies. Comparison of selected pre- and postprocedural 
clinical, haemodynamic, and echocardiographic variables 
was performed using the Student t test for paired sam-
ples. Independent groups were compared using the c2 test. 
Survival probability was determined separately in Group 1 and 
Group 2. Survival differences were shown using cumulative 
Kaplan-Meier curves, and the significance of survival dif-
ferences between the two groups was evaluated using the 
log-rank test. P < 0.05 was considered statistically significant. 
Statistical analysis was performed using the STATISTICA data 
analysis software system, version 10 (StatSoft, Inc. 2011, 
www.statsoft.com).
RESULTS
Since January 2009 till the end of 2011, 93 inoperable pa-
tients with symptomatic degenerative AS were selected for 
TAVI at the National Institute of Cardiology. Most patients 
were women (n = 60, 64.5%). Overall, the mean age was 
81.3 ± 7.1 years (range 54–91 years). Preprocedurally, 
echocardiography showed the mean peak aortic gradient 
of 99.03 ± 23.3 mm Hg and the mean aortic valve area 
of 0.66 ± 0.13 cm2. The mean log ES was 25.3 ± 12.4%. 
Group 1 included 59 (63.4%) patients with log ES ≥ 20%, and 
Group 2 included 34 (36.6%) patients with log ES < 20%. 
The mean log ES was 30.9 ± 9.7% (range 20–59.2%) in 
Group 1 compared to 12.7 ± 4.9% (range 2.86–19.27%) in 
Group 2 (p < 0.01).
The most common causes of inoperability in patients with 
log ES < 20% included advanced osteoporosis with previous 
spine compression fractures in 14 (41.2%) patients, advanced 
chronic obstructive pulmonary disease (COPD) in 13 (38.2%) 
patients, and porcelain aorta in 5 (14.7%) patients. Other 
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reasons for which the patients were not considered suitable 
candidates for surgery included previous chest radiotherapy, 
previous stroke with a neurological deficit, previous cardiac 
surgery, morbid obesity, and significantly limited mobility. Of 
note, some patients had multiple comorbid conditions that 
significantly increased the operative risk.
Compared to Group 2, patients in Group 1 were older 
(82.9 ± 5.9 vs. 78.7 ± 7.8 years, p = 0.009), had lower left vent-
ricular ejection fraction (LVEF; 51.5 ± 14% vs. 60.4 ± 9.6%, 
p = 0.002), higher pulmonary artery systolic pressure (56 ± 11 
vs. 49 ± 10.6 mm Hg, p = 0.02), and worse renal function (glo-
merular filtration rate: 51.3 ± 18.4 vs. 60.6 ± 16.6 mL/min/m2, 
p = 0.02). Comparison of the two groups is shown in Table 1.
30-day outcomes
Transcatheter aortic valve implantation was successfully per-
formed in 92 (98.9%) patients. In 1 case, a 90-year-old patient 
in Group 1, implantation of an Edwards Sapien valve was not 
possible due to a tortuous course of and calcifications in the 
femoral artery which precluded insertion of a appropriate-
ly-sized vascular sheath. The procedure was concluded with 
aortic valve balloon valvuloplasty that resulted in a significant 
reduction of the aortic gradient.
Of the remaining 92 patients, 48 (52.2%) had a CoreValve 
device implanted, and an Edwards Sapien or Sapien XT valve 
was used in 44 (47.8%) patients. When selecting the approach 
route, a transvascular approach via the femoral or subclavian 
artery was considered first, followed by a possibility of valve 
implantation via the transapical approach. The decision 
regarding the approach route was based on CT angiography 
findings. Most patients were treated using a transvascular 
approach, including via the femoral artery in 66 (71.0%) pa-
tients and vie the subclavian artery in 9 (9.7%) patients. The 
transapical approach was used for aortic valve implantation in 
18 (19.3%) patients. No difference in the choice of the access 
route was found between the two groups. Table 2 summarises 
the types of valves used and the access routes in both groups.
Immediately after the procedure, the peak aortic gradi-
ent by echocardiography decreased from 95.5 ± 27.4 to 
16.47 ± 8.15 mm Hg in Group 1 (p < 0.001) and from 
104.2 ± 18.6 to 17.16 ± 7.44 mm Hg (p < 0.001) in 
Table 1. Baseline clinical and echocardiographic patient characteristics
Variable Group 1 (log ES ≥ 20%)
N = 59
Group 2 (log ES < 20%) 
N = 34
P
Age [years] 82.9 ± 5.9 78.7 ± 7.8 0.01
Women 37 (62%) 22 (64%) NS
Logistic EuroSCORE 30.9 ± 9.7% 12.7 ± 4.9% < 0.001
Society of Thoracic Surgeons Risk Score 9.7 ± 4% 5.0 ± 2% < 0.001
Peak aortic gradient 95.5 ± 27.4 104.2 ± 18.6 NS
Coronary artery disease 39 (66%) 19 (55.9%) NS
Previous myocardial infarction 15 (25.4%) 7 (20.6%) NS
Previous PCI 16 (27.1%) 11(32.4%) NS
Previous CABG 8 (13.6%) 4 (11.8%) NS
Left ventricular ejection fraction 51.5 ± 14% 60.4 ± 9.6% 0.002
NYHA class II 14/59 (23.7%) 6/34 (17.6%) NS
NYHA class III 40/59 (67.8%) 25/34(73.5%) NS
NYHA class IV 5/59 (8.5%) 3/34 (8.8%) NS
Pulmonary artery systolic pressure [mm Hg] 56 ± 11 49 ± 10.6 0.02
Diabetes 14 (23.7%) 7 (20.6%) NS
Previous stroke/transient ischaemic attack 7 (11.9%) 2 (5.9%) NS
Glomerular filtration rate 51.3 ± 18.4 60.6 ± 16.6 0.02
Atrial fibrillation 22/59 (37.3%) 12/34 (35.3%) NS
CABG — coronary artery bypass grafting; NYHA — New York Heart Association; PCI — percutaneous coronary intervention
Table 2. Access route and the type of implanted aortic valve
Group 1 Group 2 P
Access route N = 59 N = 34
Femoral artery 40 (67.8%) 26 (76.5%) NS
Subclavian artery 4 (6.8%) 5 (14.7%) NS
Transapical approach 15 (25.4%) 3 (8.8%) NS
Valve type N = 58 N = 34
Edwards Sapien/ 
/Sapien XT
33/59 (56.9%) 11/34 (32.4%) 0.04
CoreValve 25/59 (43.1%) 23/34 (67.6%) 0.04
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Group 2. Moderate perivalvular aortic regurgitation was observed 
postprocedurally in 4 (6.8%) patients in Group 1 and 1 (2.9%) 
patients in Group 2 (p = NS). 
At 30 days after the implantation, overall 7/93 (7.5%) pa-
tients died, including 5/59 (8.5%) in Group 1 and 2/34 (5.9%) 
in Group 2 (p = NS). All deaths were cardiac deaths according 
to the VARC-2 definition [15]. Two deaths in Group 1 occurred 
during TAVI, including one due to myocardial infarction 
caused by occlusion of the left main coronary artery by a calci-
fied valve leaflet and one due to a vascular complication. One 
death occurred at 8 days after TAVI due to pulseless electrical 
activity in a patient with LVEF of 20%, and two sudden deaths 
occurred several days after hospital discharge. In Group 2, 
aortic annulus rupture occurred in 1 patient during TAVI 
who died despite immediate surgery, and the other death 
was a sudden cardiac death due to ventricular fibrillation at 
1 day after the procedure.
Major vascular complications according to the VARC-2 def-
inition occurred after TAVI in 16 (17.2%) patients, including 
10/59 (16.95%) patients in Group 1 and 6/34 (17.6%) patients 
in Group 2 (p = NS). Transfusion of > 3 units of blood due 
to anaemia after the procedure was required in 4 (6.8%) pa-
tients in Group 1 and 1 (2.9%) patient in Group 2 (p = NS). 
One transient ischaemic attack was observed but no strokes 
occurred. In addition, 1 patient in Group 1 with pulmonary 
hypertension and a history of COPD developed respiratory 
failure that lasted several months and required ventilator 
therapy for several weeks.
Pacemaker implantation was necessary following TAVI in 
21/93 (22.6%) patients. In all cases, the indication for pacing 
was the development of left bundle branch block associated 
in with first degree atrioventricular block seen after TAVI. 
Pacemaker implantation was needed in 5/44 (11.4%) patients 
with an Edward Sapien or Sapien XT valve, compared to 
16/48 (33.3%) patients with a CoreValve device (p = 0.02).
Long-term outcomes
The mean duration of follow-up was 24.8 ± 14.5 months 
(range 0–54 months). Overall, 23/59 (39.0%) patients in 
Group 1 and 7/34 (20.6%) patients in Group 2 died, includ-
ing 19/59 (32.2%) patients in Group 1 and 4/34 (11.8%) 
patients in Group 2 between 30 days after the procedure 
and the end of follow-up. Cardiovascular death occurred in 
12/19 (63.2%) patients in Group 1 and in 2/4 (50.0%) patients 
in Group 2. One-year survival in Group 1 was 76.6%, and 
2-year survival was 69.0%, compared to 89.0% and 83.6%, 
respectively, in Group 2. Cardiovascular mortality rates 
at 1 and 2 years of follow-up were significantly higher in 
Group 1 compared to Group 2 (21.4% and 28.6% vs. 8.1% 
and 10.8%, respectively, p = 0.02). Kaplan-Meier survival 
curves for freedom from death and freedom from cardiovascu-
lar mortality in Groups 1 and 2 are shown in Figures 1 and 2.
DISCUSSION
Although TAVI has been used for just more than 10 years, the 
method has been widely accepted and is commonly used 
in the treatment of selected patients with symptomatic AS. 
Initially, only patients considered definitively unsuitable for 
surgical treatment and high surgical risk patients were referred 
for TAVI but recently, also moderate risk patients became 
treated with TAVI in many centres. It is currently debated 
whether moderate risk patients should be treated surgically 
or some of them, especially older patients, might be better 
treated with TAVI. Increasing use of TAVI in older moderate 
risk patients is based on registry data showing that outcomes 
of TAVI in moderate risk patients are superior compared 
to those in high surgical risk patients [3, 16–18]. It is also 
known that surgical outcomes in older patients are worse 
than in younger patients [19, 20]. Recently, a randomised trial 
Figure 1. Kaplan-Meier survival curves for freedom from all-
-cause mortality during follow-up (months) among patients 
with logistic EuroSCORE ≥ 20% and < 20%
Figure 2. Kaplan-Meier survival curves for freedom from 
cardiovascular mortality during follow-up (months) among 
patients with logistic EuroSCORE ≥ 20% and < 20%
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comparing surgical treatment to TAVI in high and moderate 
risk patients has been reported, showing a significantly lower 
mortality at 1 year in the TAVI group compared to surgically 
treated patients [21].
The aim of our study was to compare TAVI outcomes in 
patients with log ES ≥ 20% and < 20%. Log ES was below 
20% in more than one third of patients (36.6%) referred for 
TAVI in our centre which means that these patients were 
not selected for surgical AVR due to concomitant conditions 
that were not included in the risk scores. The mean log ES in 
Group 1 was 30.9 ± 9.7% compared to more than twofold 
lower value of 12.7 ± 4.9% in Group 2. However, other 
concomitant conditions were considered significant enough 
to affect the decision of the Heart Team regarding further 
treatment approach.
Immediate outcomes
In our study group, 30-day mortality was similar in both study 
groups. Our outcomes are also similar to outcomes reported 
in other studies. In a metaanalysis that included more than 
3000 patients treated with TAVI, 30-day mortality ranged from 
1.7% to 14.3%, mean 7.8% [22]. Results of a large multicentre 
registry in the United States have been published recently. 
This study included 41 centres with 489 inoperable patients 
with severe AS. The mean patient age was 83.2 years, and 
the mean log ES was 22.6%, similarly to our study. All patients 
had a CoreValve device implanted, and 30-day mortality 
was 8.4% [23]. In several studies that included moderate risk 
patients, an association between log ES and 30-day mortality 
was found. In a study in 165 patients, Tamburino et al. [10] 
found that 30-day mortality after TAVI was 15.6% in those 
with log ES ≥ 20% but much lower (2.4%) in those with 
log ES < 20%. Similar results were reported by Wenaweser 
et al. [13] who divided 389 patients treated with TAVI into 
three groups depending on the operative risk by the STS risk 
score: low risk patients with STS < 3%, moderate risk patients 
with STS 3–8%, and high risk patients with STS > 8%. Low 
risk patients were significantly younger. It was found that 30-
day mortality was related to the STS risk score and was 2.4%, 
3.9%, and 14.9%, respectively, in low, moderate, and high 
risk patients. The authors then selected those patients who 
had their aortic valve implanted via the transfemoral approach 
and showed best outcomes in the low risk subgroup, with 30-
day mortality of 0% compared to 3.5% in the moderate risk 
subgroup and 14.7% in the high risk subgroup. In our study, 
we found no difference in 30-day mortality between the two 
groups. The rate of complications was also similar in both study 
groups. In both studies cited above, a high 30-day mortality 
of about 15% among high risk patients was notable. In our 
study, 30-day-mortality among patients with log ES ≥ 20% was 
lower at 8.5%. It seems that these results may be explained 
by a low number of patients included in our study.
Long-term outcomes
In our study, overall mortality was 28.4% at 1 year and 
35.2% at 2 years. In the historic PARTNER study, 2-year 
mortality was 43.3% in the inoperable cohort and 33.9% 
in the high surgical risk cohort [1, 24]. Our results are very 
similar to those reported by Toggweiler et al. [25] who found 
that 1-year survival after TAVI was 83%, 2-year survival was 
74%, and 5-year survival was 35%. In the multicentre United 
States registry cited above, 1-year mortality among inoperable 
patients was 24.3% [23]. Tamburino et al. [10] found that at 
1 year after TAVI, mortality in the log ES ≥ 20% group was 
25.7% compared to 6.8% in the log ES < 20% group. In the 
study by Wenaweser et al. [13], mortality at 1 year was 10.1% 
vs. 16.1% vs. 34.5%, respectively, in patients with STS score 
risk of < 3%, 3–8%, and > 8%. In our study, we did not find 
a difference in overall mortality during long-term follow-up 
but cardiovascular mortality rate was significantly higher 
among patients with log ES ≥ 20% compared to those with log 
ES < 20%. Our findings confirm the importance of risk scores 
for predicting long-term TAVI outcomes in inoperable or high 
surgical risk patients and clearly show that the outcomes of 
TAVI are better in patients with lower log ES values. 
At the 2014 ACC Scientific Sessions, a study was re-
ported that randomised high risk patients with severe AS to 
two groups: 390 patients with log ES of 17.7 ± 13.1 were 
referred for percutaneous implantation of a CoreValve device, 
and 357 patients with log ES of 18.6 ± 13.0 were referred 
for surgical valve replacement. At 1 year, a significantly lower 
mortality was found in the TAVI group (14.2%) compared to 
the surgical group (19.1%) [21]. It was the first randomised 
study that showed lower mortality following TAVI compared 
to surgical treatment. Currently, two other randomised trials 
are underway, the Surgical Replacement and Transcatheter 
AorticValve Implantation (SURTAVI) study evaluating the 
Core Valve device, and the Placement of AoRtic TraNscathetER 
(PARTNER 2) study evaluating the SAPIEN XT valve. Results 
of these studies will allow determination of the role of TAVI 
in the management of moderate surgical risk AS patients.
CONCLUSIONS
The results of this study demonstrate that at 2 years of 
follow-up, TAVI in high-risk patients with log ES ≥ 20% was 
associated with a higher cardiovascular mortality compared 
to high-risk patients with log ES < 20%. (??)
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S t r e s z c z e n i e
Wstęp: Przezcewnikowa implantacja zastawki aortalnej (TAVI) jest ustaloną metodą leczenia wybranych chorych ze zwężeniem 
zastawki aortalnej. Według wspólnego stanowiska ekspertów, Europejskiego Towarzystwa Torakochirurgów i Kardiochirurgów, 
Europejskiego Towarzystwa Kardiologicznego i Asocjacji Interwencji Sercowo-Naczyniowych, opublikowanego w 2008 r. TAVI 
powinno się wykonywać u chorych z grupy wysokiego ryzyka chirurgicznego z logistic EuroSCORE (log ES) ≥ 20%. Istnieje 
natomiast niewiele doniesień na temat TAVI u pacjentów z grupy wysokiego ryzyka chirurgicznego, ale z log ES < 20%. 
Cel: Celem pracy było porównanie wyników TAVI u chorych z log ES ≥ 20% z rezultatami uzyskanymi u pacjentów z log ES < 20%, 
którzy ze względu na inne choroby współtowarzyszące zostali ostatecznie zdyskwalifikowani z leczenia operacyjnego.
Metody i wyniki: W okresie od stycznia 2009 do grudnia 2011 r. TAVI wykonano u 93 chorych, którzy zastali podzieleni 
na dwie grupy. Grupę 1 stanowiło 59 (63.4%) pacjentów z log ES ≥ 20%, a grupę 2 — 34 (36,6%) osób z log ES < 20%. 
Średnia wartość Log ES wynosiła 30,9 ± 9,7% w grupie 1 oraz 12,7 ± 4,9%  w grupie 2 (p < 0,001). Chorzy z grupy 1 byli 
starsi (82,9 ± 5,9 vs. 78,7 ± 7,8 roku; p = 0,01), charakteryzowali się niższą frakcją wyrzutową lewej komory (51,5 ± 14% 
vs. 60,4 ± 9,6%; p = 0,002), wyższym ciśnieniem skurczowym w tętnicy płucnej (56 ± 11 vs. 49 ± 10,6 mm Hg; p = 0,02) 
oraz gorszą funkcją nerek (GFR 51,3 ± 18,4 vs. 60,6 ± 16,6 ml/min/m2; p = 0,02). Przeżycie po roku i po 2 latach było 
porównywalne i wynosiło 76,6% i 69,0% oraz 89,0% i 83,6% odpowiednio w grupie 1 i 2 (p = NS), natomiast częstość wy-
stępowania zgonów sercowych po roku i po 2 latach była istotnie wyższa w grupie 1 (21,4% i 28,6%) niż w grupie 2 (8,1% 
i 10,8%) (p = 0,02).
Wnioski: Wyniki niniejszej pracy pokazują, że częstość występowania zgonów sercowych w okresie 2-letniej obserwacji po 
TAVI jest wyższa u chorych z grupy wysokiego ryzyka chirurgicznego z log ES ≥ 20% niż u pacjentów zdyskwalifikowanych 
z leczenia chirurgicznego przez Zespół Sercowy, ale z log ES < 20%. 
Słowa kluczowe: zwężenie zastawki aortalnej, przezcewnikowa implantacja zastawki aortalnej, logistic EuroSCORE
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